Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

NCT07402044 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-03-15
Last updated
2026-03-27

Condition(s) studied

CABOTEGRAVIRLENACAPAVIR

Study summary

The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
* Age ≥18 years * HIV-1 infection * Patients who started taking cabotegravir combined with lenacapavir between July 2024 and the one-year follow-up, or who are due to start taking the CAB/LEN combination. * Patients who are due to start the CAB/LEN combination following a medical decision. Exclusion Criteria: * Participants' objection to the use of follow-up data

Primary outcome measure(s)

  • Percentage of participants with virological failure — Week 48
    Two consecutive viral load (VL) measurements ≥50 copies/mL after having achieved VL \<50 copies/mL
  • Percentage of participants with virological failure — Week 24
    ii. A single VL ≥50 copies/mL followed by permanent treatment discontinuation or loss to follow-up after previously achieving VL \<50 copies/mL; or discontinuation with VL ≥50 copies/mL
  • Percentage of participants with virological failure — Week48
    A VL ≥50 copies/mL

Trial sites (13)

FacilityCityRegionStatus
Victor Dupuy Hospital Argenteuil France
Pellegrin Hospital Bordeaux France
Saint André Hospital Bordeaux France
Raymond poincaré Hospital Garches France
Franco-British Hospital (Fbh) Levallois-Perret France
Hotel Dieu Hospital Nantes France
Archet 1Hospital Nice France
Bichat Claude Bernard Hospital Paris France
Hotel Dieu Hospital Paris France
Necker Hospital Paris France
Pitié Salpêtrière Hospital Paris France
Saint Antoine Hospital Paris France
Tourcoing Hospital Tourcoing France

More Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba trials in France

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07402044 on ClinicalTrials.gov ↗ ← All trials in France